Cellyan Biotechnology posted a net loss of $1.14 million, widening from a net loss of $27,056.
Revenue fell 34% to $13.43 million, driven by a 39% drop in Supply Chain Services to $7.56 million.
Procurement and Distribution revenue slid 22% to $5.87 million on intensified competition and exits from low-margin, slow-paying customers.
Gross profit dropped 43% to $1.39 million, cutting gross margin by 2 percentage points to 10% as pricing was lowered to stay competitive.
Cash and cash equivalents totaled $221,841, with $9.11 million in working capital; the company also cited $1.4 million in fund-disposal proceeds received by June 30, 2026.
HKPD•
